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Abstract: This study aimed to determine whether osteopathic manipulation of the T9–T10 vertebrae
improves the evolution of tonsillitis. A randomized, stratified, controlled clinical trial with blinded
patients, evaluator and data analyst was performed. The patients in the control group (CG) under-
went a “sham” manipulation. A high-speed, low-amplitude technique was applied to the T9–T10
vertebrae in the osteopathic manipulative group (OMG) patients. The number of days needed to
resolve the tonsillitis was significantly lower (p = 0.025) in the OMG (2.03 ± 0.95 days) than the CG
(2.39 ± 0.82 days). Additionally, the number of episodes of tonsillitis after the treatment decreased
significantly more in the OMG (0.8 ± 1.88 episodes/year in total) than the CG (2 ± 2.12) (p = 0.005).
In the OMG, 60.8% had no recurrences of tonsillitis, compared to 22.5% of the CG, in the following
year (χ2 (1) = 15.57, p < 0.001). No patients reported adverse effects. It has been concluded that during
an episode of tonsillitis, the number of days to resolution was significantly lower after the application
of an osteopathic manipulation of the T9–T10 vertebrae, compared to a sham manipulation. The
number of subsequent year tonsillitis episodes was greatly reduced in both groups, significantly
more in the OMG than in the CG patients.
Keywords: tonsillitis; osteopathy; manual therapy; physical therapy; spinal manipulation; OMT;
otorhinolaryngology; otolaryngology; tonsillectomy
1. Introduction
Palatal tonsillitis, either acute, recurrent or chronic, is a relatively common disease [1],
especially in childhood [1,2]. The treatment of choice is the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) and/or antibiotics [1,3,4], and in some cases tonsillec-
tomy [5–9]. These treatments can present side effects [5,6,10–13] in the short and long
term [14]. Each episode of tonsillitis also implies costs related to absence from work
and school [1,9,10,15]. With tonsillectomy, adults experience a sore throat for an average
of 13 to 17 days [10,12]. In addition to being painful [9,10], the risk of iatrogenic mor-
bidity [6,7,9,10,16,17] and mortality [5,6,16] of tonsillectomy must be taken into account.
Although tonsillectomies have decreased in recent decades [18] (except for cases of sleep
apnea due to hypertrophic tonsils and recurrent tonsillitis) [6,7,19,20], it is still one of the
most frequent surgical interventions [6,9,10,15]. Tonsillectomy rates vary greatly between
countries [18]. Among alternative and complementary medicine interventions, spinal
manipulations have been used to treat tonsillitis. Through occiput-cervical manipulation, a
favorable evolution has been obtained in recurrent or chronic childhood tonsillitis, in which
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a high rate of pathological blockages of joints was also found [21]. This favorable evolution
might be due to the fact that spinal manipulation may influence the biomarkers of local
and systemic inflammation [22,23]. However, cervical manipulations are considered riskier
manipulations, although severe complications are very rare [24–27]. Manipulation of the
thoracic vertebrae presents fewer severe adverse events than cervical manipulation [25,27].
Furthermore, the vertebral segments T9 and T10 innervate the adrenal glands [28–31],
which produce cortisol, and patients with tonsillitis have been found to have altered cor-
tisol levels [32]. This hormone may influence the immune response [22,33,34], and its
levels are modified after thoracic manipulation [22,23,35,36]. Thus, in a prospective study
(75 participants) without a control group, manipulation of the lower thoracic vertebrae
(mainly in the T9–T10 segments), obtained 55% resolution sooner than 24 h and 76% sooner
than 48h, showing promising results for treating tonsillitis in both children and adults [37].
The objective of the present study is to determine if osteopathic manipulation of the T9–T10
vertebrae improves the evolution of tonsillitis, under the hypothesis that it produces a
decrease of days with symptoms and a decrease in recurrences. In addition, it is intended
to analyze the possible influencing factors.
2. Materials and Methods
2.1. Design
A stratified, randomized placebo trial was conducted with blinded patients, evaluator
and data analyst. The study was carried out between 2-21-2014 and 6-30-2018 in the private
center of Physiotherapy and Osteopathy of the main researcher of the study, in the city
of Cáceres (Spain). The study was prospectively registered (ACTRN12612000068864), it
followed the principles of the Declaration of Helsinki in its latest version [38] and was
approved by the Ethics Committee of the University of Seville.
2.2. Participants
The participants were recruited from a Physiotherapy and Osteopathy Health Center,
a pediatrician’s office, a General Medicine office, and a private clinic (in its Emergency
Service and in a General Medicine office). Independently of the place where the recruitment
took place, the participants were diagnosed by a collaborating physician who also visually
measured the tonsil at enrollment in order to classify it in degrees (0-IV) according to
the occupation of the oropharyngeal space [2]. Participants of both sexes between 3 and
65 years old diagnosed with acute or recurrent tonsillitis of less than 48 h of evolution,
or chronic tonsillitis in the symptomatic phase, were included in the study. Those vacci-
nated or treated with immunomodulators (immunoferon and the like) [39] during three
previous years to recruitment, any subject who was suffering an episode of pharyngitis or
adenoiditis without palatal tonsillitis (i.e., tonsillectomized), being treated with antibiotics
immediately before the tonsillitis episode, subjects who did not provide a phone number
in the initial questionnaire for control calls and subjects who presented contraindications
to the experimental treatment [40,41] were excluded. Before the start of the study, all
participants or their parents or guardians in case of minor signed an informed consent
form.
2.3. Treatment Protocols
The subjects were randomly assigned to the study groups by using two computer-
generated (Microsoft Excel) tables of sequence of numbers (2:1 ratio experimental/control),
one table for those participants treated with antibiotics and the other one for those who
were not, in order to avoid between-groups differences related to antibiotic use. The
randomization sequence was guarded by an independent collaborator who guaranteed
its concealment. To implement random allocation, sequentially numbered opaque sealed
envelopes were used. Those researchers and collaborators who recruited the sample were
blinded to the number sequence and to the intervention assignment. Additionally, every
intervention was blinded for both the participants and evaluators. The patients in the
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control group (CG) underwent sham manipulation, consisting of a careful 150◦ passive
flexion of the shoulders, with gentle contact of the osteopath’s knees in the middle thoracic
vertebrae, without impulse or causing tension. (Figure 1)
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The osteopathic manipulative procedure or the sham manipulation were only applied
once, as soon as possible after the enrollment, always in the first 48 h of the beginning of
the symptoms of that episode of tonsillitis. The same physiotherapist—osteopath, with
professional experience of more than 20 years, applied the interventions to both groups.
This researcher did not participate in the recruitment, randomization, evaluation nor
statistical analysis, being blinded to all of those processes.
Regardless of the application of the experimental procedure or placebo, all subjects
continued pharmacological treatment (analgesics, NSAIDs and/or antibiotics) prescribed
by their doctor.
2.4. Evaluations
The main results were the number of days for the total resolution of the symptoms of
tonsillitis (fever, sore throat, cough, etc.) and the number of episodes of tonsillitis during
the following year. Both were measured by telephone consultation [45–48]. The number
of days for the resolution of the symptoms was evaluated seven days after the application
of the experimental treatment or the placebo maneuver, and the result was also classified
as excellent (resolution in less than 24 h), good (resolution in less than 48 h), moderate
(improvement from the first day, but with resolution ≥48 h) or poor (no improvement
on the first day, with resolution ≥48 h). The number of recurrences during the following
year was evaluated through monthly telephone calls for 12 months. In the case of those
participants younger than 18 years old, all the information was given by their parents or
tutors. As secondary results, the different associations between the variables measured
were evaluated. The independent variables were collected through the initial questionnaire
filled out by the patient and the initial clinical examination carried out by the collaborating
physician. In addition to the outcome variables, age, gender, season of the year, degree of
tonsillar hypertrophy, consumption of NSAIDs, paracetamol and prescribed antibiotics
were recorded. Additionally, we also registered the number of episodes in the two years
prior to the study, the scheduling of tonsillectomies, the presence of a fever, odynophagia,
cough, pultaceous tonsillitis, mucus the previous days, ear pain or infection, habitual nasal
voice, nasal voice during the episode, habitual snoring, snoring during the episode or
adenitis greater than 2 cm.
From the moment that the participants were included in the study, they were adverted
about the information they would be asked by phone, so that they had to pay attention
and control it. For instance, they were asked to assess any sign of hyperthermia thermo-
metrically. In the case of participants younger than 18 years old, all of this was explained
to their parents or tutors.
2.5. Statistical Analysis
Statistical analysis was carried out with SPSS 22.0 software (SPSS Science, Chicago, IL,
USA). The descriptive study of the variables was carried out in tables with mean, standard
deviation, 95% confidence interval (CI) for continuous variables and in percentages for
qualitative variables. Before carrying out the statistical analysis, the conditions of its
application were considered; the Shapiro–Wilk test was used to verify that the sample met
normality criteria. The Mann–Whitney U test was used to verify homogeneous distribution
between groups when they did not meet normality criteria; otherwise, the T test was
used. Chi-square was used for qualitative variables. A least squares estimation was used
to quantify the interval of difference between groups. Analysis of variance of repeated
measures (ANOVA) with linear model with Bonferroni adjustment was used to test the
profile of the change in the result of the number of episodes in the two and one year before
and after the two study groups, and the comparison in pairs according to time and group.
The global clinical effects for the repeated measures analysis were calculated using the
Eta-squared value (η2), categorized as small = 0.01, medium = 0.06 and large = 0.14 [49].
For the analysis of the number of days of resolution, the Mann–Whitney U test was used.
Pearson’s chi-square was used for the analysis according to group of the resolution greater
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than 48 h, initial result and at 12 months. The bivariate correlations of the quantitative
variables were analyzed using Pearson’s coefficient. A significance level p < 0.05 and a
confidence level of 95% were established. Finally, participants under 18 years old were
considered as children.
The sample size calculation was performed (GRANMO v7.12; IMIM Hospital del Mar–
Barcelona–Spain) for the proportion of cases resolved in the first 48 h after the application
of the intervention. An alpha level of 0.05 and a desired power (beta) of 80% with a
bilateral contrast were assumed. Additionally, the sample size was estimated according to
an expected proportion of resolutions of 65% in the first 48 h in the OMG and a proportion
of 36% in the CG. Losses were estimated at 15%. These assumptions generated a sample
size of 80 participants in OMG and 40 in CG.
3. Results
3.1. Sample
While all of the 40 subjects randomized to CG completed the study, one of the eighty-
one subjects randomized to OMG never answered the phone calls, so they were considered
as a withdrawal. (Figure 3)
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Thus, 120 subjects (70 women) aged between 3 and 57 years (23.53 ± 14.84 years)
completed this study. No between-groups differences were found for any of the baseline
characteristics (p > 0.05 for all variables). (Table 1).
Comparing the number of episodes two years before with that of the previous year,
there was a significant increase in OMG (p = 0.011) and a clear similar trend in CG (p = 0.052).
This increase occurred both in children (with a change from 4.79 episodes two years earlier,
to 6.10 in the previous year) and in adults (from 4.19, to 4.94). There was a negative
correlation between age and the number of episodes in the previous year (r = −0.186;
p = 0.042). Tonsillar hypertrophy was more prevalent in males (p = 0.035), in those under
18 years of age (p = 0.009) and among those who snored during the episode (p = 0.047). As
for the pediatric sample, when compared with the adult participants, it had a higher male
composition (p = 0.033), had a higher prevalence of nasal mucus (p = 0.004) and snoring
during episodes (p = 0.018).
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Characteristics Mean/n SD/% Mean/n SD/% p-Value
Age (years) (n = 120) 25.30 15.11 22.64 14.73 0.439
N◦ episodes 2 years before (n = 116) 4.75 3.95 4.21 3.61 0.435
N◦ episodes 1 year before (n = 120) 5.45 4.13 5.16 3.89 0.781
Sex (n =120) Male 17 42.5% 33 41.3% 0.896Female 23 57.5% 47 58.8%
Fever (n =120) No (Temperature <37.5
◦C) 10 25.0% 21 26.3%
0.883Yes (Temperature ≥37.5 ◦C) 30 75.0% 59 73.8%
Pain or odinophagy (n = 119) No 0 0.0% 4 5.1% 0.148Yes 40 100.0% 75 94.9%
Cough currently (n = 118) No 22 55.0% 32 41.0% 0.149Yes 18 45.0% 46 49.0%
Levels of tonsilar hypertrophy
(n = 115)
The pillars do not protrude 1 2.6% 5 6.7%
0.760
Occupy less than 25% of the
space 9 23.1% 16 21.3%
Occupy 25–49% of the space 12 30.8% 20 26.7%
Occupy 50–74% 14 35.9% 31 41.3%
Occupy >75% 3 7.7% 3 4.0%
Mucus days before the episode
(n = 119)
No 16 40.0% 28 35.4%
0.627Yes 24 60.0% 51 64.6%
Pain or infection of ears
(n = 119)
No 25 64.1% 47 58.8%
0.575Yes 14 35.9% 33 42.3%
Usual nasal voice (n = 119) No 32 80.0% 58 73.4% 0.429Yes 8 20.0% 21 26.6%
Nasal voice in the episode
(n = 119)
No 6 15.0% 11 13.9%
0.874Yes 34 85.0% 68 86.1%
Snore usually (n = 117) No 22 56.4% 56 71.8% 0.096Yes 17 43.6% 22 29.2%
Snore during the episode
(n = 116)
No 11 28.2% 30 39.0%
0.252Yes 28 71.8% 47 61.0%
Take prescribed antibiotics
(n = 120)
No 18 45.0% 37 46.3%
0.897Yes 22 55.0% 43 53.8%
Take prescribed NSAID
(n = 119)
No 6 15.0% 22 27.8%
0.119Yes 34 85.0% 57 72.2%
Take prescribed paracetamol
(n = 120)
No 15 37.5% 38 47.5%
0.298Yes 25 62.5% 42 52.5%
Pultous tonsilitis (n = 117) No 24 61.5% 49 62.8% 0.893Yes 15 38.5% 29 37.2%
Palpable adenitis over 2 cm
(n = 116)
No 5 13.2% 21 26.9%
0.095Yes 33 86.8% 57 73.1%
Station (n = 120)
Spring 8 20.0% 13 16.3%
0.673
Summer 8 20.0% 12 15.0%
Autumn 9 22.5% 26 32.5%
Winter 15 37.5% 29 36.3%
SD, standard deviation; NSAID, non-steroidal anti-inflammatory drugs.
3.2. Intervention Effects on Tonsillitis
The number of days needed to resolve the tonsillitis was significantly lower (PSest = 0.247;
p = 0.025) in the OMG (2.03 ± 0.95 days) than the CG (2.39 ± 0.82 days). In the case of the
adults, this significant difference persisted (PSest = 0.263; p = 0.001), with better results for
the OMG (2.00 ± 0.81 days) compared to the CG (2.44 ± 0.61 days), but not in the pediatric
participants (p = 0.856; OMG 2.00 ± 1.00 days; CG 1.91 ± 0.83 days).
The 63.75% of the subjects of the OMG resolved the episode in less than 48 h, compared
to 42.5% in the CG (Table 2). In the case of adults, 68.6% of the subjects of the OMG resolved
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the episode in less than 48 h, compared to 33.3% in the CG, showing a significant difference
with medium effect size, which was not present in children.
Table 2. Distribution of the results in the first week (E = Excellent, G = Good, M = Moderate and P = Poor) in relation to the
group to which they belonged (CG = Control Group, EG = Experimental Group) and according to age.
Results 1st Week Results 1st Week Grouped
Group E G M P E + G (Resolution< 48 h)
M + P (Resolution
≥ 48 h)
CG 5 (12.5%) 12 (30.0%) 14 (35.0%) 9 (22.5%) 17 (42.5%) 23 (57.5%)
EG 20 (25.0%) 31 (38.75%) 11 (13.75%) 18 (22.5%) 51 (63.75%) 29 (36.25%)
p value χ2 (3) = 8.35, p = 0.039, V = 0.264 χ2 (1) = 4.90, p = 0.022, V = 0.202
Children
CG 4 (30.7%) 4 (30.7%) 4 (30.7%) 1 (7.7%) 8 (61.5%) 5 (38.5%)
EG 9 (31%) 7 (24.1%) 5 (17.2%) 8 (27.6%) 16 (55.2%) 13 (44.8%)
p value χ2 (3) = 2.57, p = 0.462 χ2 (1) = 0.15, p = 0.700
Adults
CG 1 (3.7%) 8 (29.6%) 10 (37%) 8 (29.6%) 9 (33.3%) 18 (66.6%)
EG 11 (21.5%) 24 (47%) 6 (11.7%) 10 (19.6%) 35 (68.6%) 16 (31.4%)
p value χ2 (3) = 11.23, p = 0.011, V = 0.38 χ2 (1) = 8.94, p = 0.003, V = 0.34
E (resolution in <24 h); G (resolution in <48 h); M (improvement on the first day, resolution ≥48 h); P (no improvement on the first day,
resolution ≥48 h).
The number of episodes of tonsillitis after intervention decreased in the CG and in the
OMG, as shown in Table 3 and Figure 4. Ten tonsillectomy cases (two from the CG and
eight from the OMG), six cases that were vaccinated (three of the CG and three of the OMG)
in the following year by their doctor and three cases of the OMG that had not registered
the number of episodes of the second previous year were excluded.
In the analysis of the number of post-treatment episodes according to age, the OMG
achieved a significant improvement when compared to the control group both in adults
(PSest = 0.25; p < 0.001; OMG 0.69 ± 1.61 episodes; CG 2.00 ± 2.07 episodes) and in children
(PSest = 0.29; p = 0.026; OMG 0.92 ± 2.26 episodes; CG 2.00 ± 2.33 episodes).
In the supporting repeated measures ANOVA including data points from two years
before, one year before and after intervention, we did not find a significant time by group
interaction effect (F (2,198) = 1.408, p = 0.247, η2 = 0.014). However, we found a significant
time interaction effect (F (2,198) = 82.897, p < 0.001, η2 = 0.456). Specifically, post hoc
analysis in both groups showed significant between-time differences (p < 0.001) in the
change from two years and one year before intervention compared to after the intervention.
Furthermore, the number of episodes of tonsillitis after the treatment decreased significantly
more in the OMG (0.8 ± 1.88 episodes in total) than the CG (2 ± 2.12) (p = 0.005).
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Recurrence 31 77.5% 31 39.2%
<0.001 χ2 (1) = 15.57No recurrence 9 22.5% 48 60.8%
In the CG, there was a significant correlation (p = 0.012) between the number of
episodes in the previous year and recurrence at 12 months, but not in OMG (p = 0.095).
Additionally, there was no correlation between age and the number of episodes in the
subsequent year (p = 0.950). Five subjects from the OMG and one from the CG did not end
up receiving the planned tonsillectomy, due to the fact that they had presented an average
of 10 episodes in the previous year. Five of them were hypertrophic.
No patients reported adverse effects, not even soreness, in relation to the manipulation
received, neither in the OMG nor in the CG.
4. Discussion
In spite of the importance of results from scientific research in evidence-based practice
for osteopaths [50], there are not many studies about the role of spinal manipulation in
tonsillitis, as previously explained [21,37].
Our study’s main objective was to explore if T9–T10 osteopathic manipulation reduces
the duration of symptoms as well as the number of recurrences in subjects with tonsillitis.
Through a randomized clinical trial, we observed that the number of days of resolution of
the episode of tonsillitis was significantly lower in the OMG than in the CG. This result
was only found in adults but not in children. Likewise, the number of episodes of tonsillitis
in the following year decreased significantly in both groups, compared to the previous
year, but significantly more in the T9–T10 manipulation group. In this case, this effect was
found in both adults and children. It should be noted that the follow-up comprised one
whole year. Furthermore, there were no intergroup differences at baseline for any variable,
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including taking antibiotics. However, the data obtained about the number of episodes
in the previous year and, even more so, two years earlier, may be subject to recall bias.
Previous studies reported an overestimation of the frequency of sore throats by parents in
retrospective-prospective studies during childhood [51]. What is more, it has to be taken
into account that children younger than three were excluded due to the low number of
tonsillitis diagnosed in the first year of life, which would affect the reported data for the
previous years. On the other hand, the great improvement in the number of episodes in
the subsequent year in both groups may be influenced by “attention bias” or Hawthorne
effect [52], since the participants received a monthly telephone call from the collaborating
nurse, and they knew they belonged to a clinical trial in which they had received treatment.
Regarding the weight of the intervention group with a 2:1 randomization, it was due to
ethical issues and the existence of indications of promising results for the experimental
intervention [37]. Finally, in spite of the fact that the phone follow-up is a reality in both
clinical and research settings [45–48], it is a limitation of the study that, in that it is based
on subjective outcomes of patients’ interview through telephone.
After childhood, there is a natural tendency for the number of episodes to decrease [1,53],
but in our study, no such trend was found in the previous two years, neither in children
nor in adults. In contrast, the number of episodes of tonsillitis increased from the two years
before to the year before participation in the study. This increase was significant in the
OMG, although not in the CG (p = 0.052), perhaps due to the smaller size of the CG.
While the influence of recall bias cannot be ruled out, this increasing trend in tonsillitis
episodes in the previous two years indicates that there was no decreasing trend in tonsillitis
episodes, either natural or due to the treatments received. Therefore, the large decrease in
episodes in the subsequent year observed in both groups does not seem attributable to the
natural course of the disease or to the conventional treatments applied to the subjects in the
sample. Furthermore, it should be remembered that vaccination and the consumption of
immunomodulators [39] the previous year were considered as exclusion criteria. Although
there was a negative correlation between age and the number of episodes in the previous
year, this correlation was small (r = −0.186), and there was no correlation with the number
of episodes in the following year (p = 0.950). Therefore, we can hypothesize that age had
little influence on the long-term result and, therefore, treatment can be considered from
three years of age.
Several studies on tonsillitis describe a decrease of 0.5 to 1 episode on average in the
subsequent year of follow-up in the control group, as shown in a recent clinical practice
guideline [2]. In a study with children and adults, the placebo group obtained 51% of the
cases without relapses in the following year [4,54], although in our CG there was a 22.5%
of cases without relapses. In our sample, the considerable decrease in post-intervention
episodes in CG led us to think that there could be a strong placebo component in both
study groups [55–57]. In one pediatric study about prophylaxis with cefpodoxime versus
placebo [4,58], the number of acute episodes at 12 months was reduced by 84% in the
intervention group compared to 15% in the placebo group. In our sample, the reduction in
the number of episodes of CG infants was much greater (64% fewer episodes, versus 83%
reduction in OMG). This makes us suppose a strong placebo effect in pediatric age in our
study, which might be increased by the fact that the parents/tutors observed the application
of the procedures. Additionally, it could make the parents/tutors more likely to report a
positive outcome. What is more, before the treatment, patients generally could already be
perceived as very hopeful, possibly because the study center has been involved in research
on this issue for years, with hundreds of cases treated in the region, which could favor the
placebo effect [59]. To this effect, the aforementioned recall bias [51] can be added, which
hypothetically would overestimate the number of episodes in the previous years, while
those in the following year would be better quantified by monthly follow-up calls. In any
case, regardless of the possible placebo effect of both groups, the number of post-treatment
episodes in the OMG was significantly lower compared to the CG.
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In the same way, although the OMG obtained a significantly faster total resolution of
symptoms than the CG for the current episode, the good short-term results in a number of
CG cases could be partly explained by this placebo effect as well [60]. However, taking up
to two days for the episode to evolve, drug treatment and spontaneous remission can also
explain these data. A Cochrane analysis [3] showed that spontaneous healing occurred in
adults on day three in approximately 40%, and that the antibiotic group healed on average
16 h (0.67 days) earlier than the placebo group (in our sample, 0.36 days formerly the OMG).
In clinical practice guidelines [1] it is considered that with adequate therapy, most patients,
especially adolescents and adults, are asymptomatic within 48 h (in our study they were
63.75% of the OMG).
Although the objective of our study was not to analyze the possible mechanisms of
action that could explain the results obtained, we think that the neuroendocrine pathway
should be considered. However, we did not evaluate neuroendocrine data, which con-
stitutes a limitation of the study. As previously explained, patients with tonsillitis show
altered cortisol levels [32], which is known to influence the immune response [22,33,34]. The
adrenal glands, which produce cortisol, are innervated by T9 and T10 levels [28–31]. Fur-
thermore, spinal manipulation may influence the biomarkers of local and systemic inflam-
mation [22,23], and specifically, thoracic manipulation modifies cortisol levels [22,23,35,36].
All of this could influence the evolution of tonsillitis. The correlation observed in CG
between the number of episodes in the previous year and recurrence at 12 months did
not occur in the OMG, which leads us to hypothesize that manipulative treatment may be
effective regardless of the number of previous episodes. In other words, a high number of
episodes in the previous year is a poor prognostic factor for recurrence in the natural course
of tonsillitis, but not after the proposed osteopathic treatment. The fact that six planned
tonsillectomies were avoided (five in the OMG), despite having presented 10 episodes
on average in the previous year and that five of them were hypertrophic, suggests that
manipulative treatment might be proposed prior to decision making or performance of
tonsillectomy, being able to prolong the expectant attitude in some nonurgent cases [2,9,10],
even when the number of previous episodes or the tonsil size suggest a possible poor
evolution. This is supported by the fact that, without adenoid hypertrophy, the size of the
palatine tonsils does not correlate with obstructive sleep apnea syndrome [2].
In our study, no distinction was made between viral and bacterial pharyngo-tonsillitis.
However, whether the doctor had prescribed antibiotics or not was controlled, either
due to antistreptolysin O titer (ASOT), clinical suspicion of bacterial infection [38] or by
confirmation by rapid antigen detection tests of GABHS or pharyngeal exudate culture. In
future studies, it would be interesting to perform rapid antigenic detection tests of GABHS,
ASOT titer and/or throat swab culture [53] on all participants to find out if the results of
T9–T10 manipulation are influenced by the etiology of tonsillitis (viral or bacterial).
5. Conclusions
During an episode of tonsillitis, the number of days to resolution was significantly
lower after the application of an osteopathic manipulation of the T9–T10 vertebrae com-
pared to the application of a sham manipulation. In most OMG patients, remission of
tonsillitis symptoms was obtained in less than 48 h, but not in CG. In addition, the number
of tonsillitis episodes in the following year was greatly reduced in both groups, significantly
more in OMG than in sham patients. More studies are needed to confirm these results and,
if confirmed, to analyze the possible mechanisms of action.
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